Phase 1 Trial to Test AL002, Targeting Brain’s Immune System, as Way of Treating Alzheimer’s

Phase 1 Trial to Test AL002, Targeting Brain’s Immune System, as Way of Treating Alzheimer’s
Alector’s candidate immune system-targeting therapy for Alzheimer’s disease, called AL002, will be evaluated for safety and tolerability in a first Phase 1 clinical trial, the company announced. AL002 is an antibody that targets and activates TREM2 (triggering receptor expressed on myeloid cells 2), a receptor selectively expressed on microglia — a group of cells that act as the

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

2 comments

Leave a Comment

Your email address will not be published. Required fields are marked *